China NMPA Drug Inspection - Tasly Pharmaceutical Group Co., Ltd. - Isatis root effervescent tablets
China NMPA drug inspection for Tasly Pharmaceutical Group Co., Ltd. published March 05, 2020. Drug: Isatis root effervescent tablets. This report, issued by the Guangdong Provincial Drug Administration on March 5, 2020 (Announcement No. 21), details the
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Tasly Pharmaceutical Group Co., Ltd. published March 05, 2020. Drug: Isatis root effervescent tablets. This report, issued by the Guangdong Provincial Drug Administration on March 5, 2020 (Announcement No. 21), details the
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox